Dual VEGF/VEGFR inhibition in advanced solid malignancies: Clinical effects and pharmacodynamic biomarkers

Our prior phase I study of the combination of vascular endothelial growth factor (VEGF) antibody, bevacizumab, and VEGF receptor (VEGFR) inhibitor, sunitinib, in advanced solid tumors identified an encouraging response evaluation. An expansion phase of this study was thus undertaken to obtain furthe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Mittal, Kriti, Koon, Henry, Elson, Paul, Triozzi, Pierre, Dowlati, Afshin, Chen, Helen, Borden, Ernest C, Rini, Brian I
Formato: Artigo
Idioma:Inglês
Publicado em: Landes Bioscience 2014
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4119082/
https://ncbi.nlm.nih.gov/pubmed/24842548
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.29187
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados